The Intersection of Kickstarter-Style Fundraising for Research and Distributed Development in Complex Problems
Posted: August 4, 2013 at 2:57 am
The success of Kickstarter and conceptually similar entities (IndieGoGo, AngelList, and so forth) as fundraising communities has more than adequately demonstrated that crowdfunding works very well in an environment of low-cost, ubiquitous communication and open data. All the old centralized time-proven activities of fundraising in for-profit business can in fact be distributed, turned inside out, and disintermediated. New middle men arise in this process of disruptive change, such as Kickstarter, but the future will see their dominance vanish in favor of open protocols and marketplaces with some sort of an ecosystem of optional gatekeepers and reviewers. This is exactly the same as the transition from early dial-up services and their walled gardens to the open internet, and seems to be something of an inevitability.
Can this be made to work for science and research? Therein lies the question. At the high level, it seems as though the answer is obviously yes: it's all just money, and money is presently invested in research. But at the detail level research is a very different thing from funding a new artwork or widget: it has a much longer time horizon, a far greater degree of uncertainty, and the funders don't walk away at the end with a new widget. A number of companies are presently attempting to find the magic recipe by which crowsourced science funding can be made work in a Kickstarter-like fashion.
Clearly crowdfunding for specific research goals is possible. There are numerous examples of success in the past decade beyond those I'll mention here. The Methuselah Foundation and SENS Research Foundation grew out of crowdfunding initiatives, raising money from hundreds of donors from the transhumanist community and other supporters of longevity science. The advocacy community of Longecity raises modest sums for specific life science research projects connected to longevity and related medical technologies. But these are tailored projects, integrated with specific interest communities: not the same thing at all as building a successful marketplace for diverse forms of project and community.
Crowdfunding intersects with another important trend that arises with ubiquitous, low-cost communication and openly accessible data, which is the distribution of effort in large projects. Complex initiatives can now be undertaken piecemeal by geographically dispersed groups who share a common interest. The open source software development community is far ahead of the rest of the world in this respect: many vital and important software projects have evolved in a worldwide fashion, with self-organizing collaborators who will never meet in person. Science is moving in the same direction: lots of data, lots of complex software, data becoming more open, and more distributed collaboration between researchers in different parts of the world.
What medical science has that the software industry does not is a vast and pervasive edifice of regulation, wherein largely unaccountable regulators insist on centralization and the imposition of enormous costs on research and its application in the form of new therapies and medical technologies. Regulation opposes movement to a more distributed research and development industry in which even exceedingly rare diseases will be worked on by someone, somewhere with a vested interest. Higher costs always mean that marginal work suffers, vanishes entirely, or takes place in black and grey markets with all their attendant issues. It is enormously harmful, and that harm is largely invisible: the technologies not developed, the progress not made, the dead in their millions who might have had a chance at longer lives.
The article quoted below offers some thoughts on all of this in the context of cancer research and proto-crowdfunding efforts that have aimed to spur research and development in therapies for very rare forms of cancers, those that present regulation makes it unprofitable to work on. The points raised are also applicable to the situation for aging and rejuvenation research, however, which is also a collection of related minority fields that are shut out from clinical application by the decisions of regulators.
Can We Build A Kickstarter For Cancer?
Building large analytical databases to mine clinical and molecular data, and scan the scientific literature to identify better treatments for cancer patients is happening today. But what about patients who fall outside what we already know - whose cancer subtypes haven't been discovered yet, and who don't have access to the technologies that could make a difference in unraveling the aberrations driving their cancers? The technology to unravel the molecular drivers of cancer is, for the most part, available today: "-omics" technologies for screening tumor samples from patients and comparing them to healthy tissue samples to pick out cancer-specific mutations; diagnostics that can track patients' response to treatment in real time at a molecular level; and Web-based tools and apps [that] patients and community oncologists can use to guide treatment decisions (and feed those outcomes, good and bad, back into the research process).
Our current research approach - one drug, one clinical trial, one cancer type at a time - won't generate enough of the information we need to unravel cancer's molecular mysteries at the patient level. And it is too slow, too bureaucratic, and too expensive to be sustainable, given the number of compounds we have to test and the limited pool of patients who participate in clinical trials. Only about 3% of all cancer patients participate in cancer clinical trials, and those patients - because of restrictive inclusion/exclusion criteria - are often very different (i.e., healthier) than the average cancer patient, who is likely to be in poorer health and have one or more co-morbidities (obesity, diabetes, etc.). This limits the applicability of even the best drug guidelines based on classical trials for real-world patients. Classical clinical trials lead to a "tyranny of the averages," rather than helping us to - as in the case of cancer - disassemble complex diseases that might share the same clinical symptoms (and which we happen to call cancer or diabetes) but which are really molecularly distinct and thus require different treatment approaches.
In short, we won't develop the drugs or complex treatment regimens we need to for truly personalized cancer treatment regimens for patients if we keep doing business as usual. The patients who have the most to gain from this approach are those who have the most to lose today - patients with rare or hard-to-treat cancers, who fail rapidly on standard or even targeted treatments. And it's exactly these patients who will, in all likelihood, be most eager to embrace the risks and promise of Kickstarting their own cancer research.
It's not just cancer: all of modern medicine would benefit from an overturning of the present centralized regulatory structures in order to allow unfettered diversity in fundraising, research, and clinical application. This is exactly the sort of approach that modern communication technologies enable: let there be far more in the way of researchers connecting to the interested small communities among the broader public - as was the case for the Strategies for Engineered Negligible Senescence - and the best of these initiatives, those that manage to obtain support from both the public and the scientific community, will prosper. This, I think, is a far more promising model for the future of research than the stasis, obstructions, and failures of highly regulated, state-funded scientific and medical monoliths.
- Grand Traverse Co. Health Department Seeks Volunteers for Hagerty Center Vaccination Clinics - 9&10 News - January 20th, 2021
- How to live longer: Should you skip breakfast to promote longevity? Doctor weighs in - Express - December 28th, 2020
- China Long Avoided Talking About Mental Health. Then Covid Hit. - The New York Times - December 22nd, 2020
- With fitness centers shut down due to COVID-19, home gyms are on the rise - SW News Media - December 10th, 2020
- Review: Equinox Takes Luxe Fitness Into The Wild at Their First Outdoor Gym in LA - InsideHook - September 30th, 2020
- Colorados fitness industry starting to reawaken, but some studios will never reopen - Loveland Reporter-Herald - June 16th, 2020
- In sickness and in health: North Spokane couple weds in front yard during pandemic - The Spokesman-Review - May 18th, 2020
- Furry Friends Provide Big Benefits - June 20th, 2018
- CT Nutrition Consultants - Registered Dietitian - July 12th, 2017
- Channel Update - Fitness & Football Videos Only! - Video - August 10th, 2014
- Measuring the Impact of Cytomegalovirus in Younger People - September 1st, 2013
- Decreased mTOR Expression Provides 20% Mean Life Span Extension in Mice - September 1st, 2013
- A Collagen Patch to Spur Heart Tissue Repair - September 1st, 2013
- Statin Use Correlates With Higher Telomerase Activity - September 1st, 2013
- Children of Long-Lived Parents Have Better Immune Systems - September 1st, 2013
- A Two-Part Report on Global Futures 2045 - August 25th, 2013
- The Next Few Years of Research Into Alzheimer's Disease - August 25th, 2013
- A Look Back at Some of the Roots of Modern Thought on Radical Life Extension - August 25th, 2013
- Damaging the Biology of Mice to Make them Age More Rapidly Often Tells Us Little of Use - August 25th, 2013
- Calorie Restriction as a Means to Augment Cancer Therapies - August 25th, 2013
- Life Without Ageing: Aubrey de Grey and Tom Kirkwood to Debate Longevity Science at the British Science Festival - August 18th, 2013
- A Short Overview of 3-D Printing in Tissue Engineering - August 18th, 2013
- Another Way to Improve Memory in Old Mice - August 18th, 2013
- SENS Research Foundation Releases 2013 Research Report - August 18th, 2013
- Targeting Redox Biology to Reverse Mitochondrial Dysfunction - August 18th, 2013
- The Cost of Living Longer, Even in Good Health - August 11th, 2013
- Signs of Progress: Insurers Talk of Radical Life Extension - August 11th, 2013
- The Current State of Knowledge of Genetics and Longevity - August 11th, 2013
- A Video Tour of Alcor and Interview With Max More - August 11th, 2013
- And Now For Something Reprehensible - August 11th, 2013
- Opposing the Argument that Increased Longevity Will Slow Progress, and is Therefore Undesirable - August 4th, 2013
- Considering State Opposition to Life Extension Technologies - August 4th, 2013
- Steps Towards a Tissue Engineered Thymus - August 4th, 2013
- The Cost of Being Tall is a Shorter Life Expectancy - August 4th, 2013
- A Little Methionine Restriction Research - June 16th, 2013
- Calorie Restriction Versus Resveratrol Treatment - June 16th, 2013
- Reviewing the Literature on Calorie Restriction and Oxidative Stress - June 16th, 2013
- Arguing By Induction For an Absence of Boredom in an Ageless, Greatly Extended Healthy Life - June 16th, 2013
- Investigating Fingertip Regeneration in Mammals - June 16th, 2013
- The Incentives Associated With Becoming a Machine Entity - June 9th, 2013
- A Good Scientific Polemic on Aging - June 9th, 2013
- Quantifying Neurogenesis in Adult Humans - June 9th, 2013
- Considering the Details of Replacing the Brain - June 9th, 2013
- Overreacting in the Direction of Doing Nothing - June 9th, 2013
- Considering the Regenerative Signals Emitted by Transplanted Stem Cells - June 2nd, 2013
- A Bioprosthetic Heart - June 2nd, 2013
- Exercise Versus Peripheral Artery Disease - June 2nd, 2013
- Bracketed by Billionaires - June 2nd, 2013
- Stem Cell Transplants for Leukemia Showing Improved Outcomes - June 2nd, 2013
- Videos from the SENS Research Foundation Evidence Studios Event in December 2012 - May 26th, 2013
- Early Mortality Rates Predict Late Mortality Rates - May 26th, 2013
- Decellularization May Enable Use of More Donor Organs - May 26th, 2013
- Mitochondrially Targeted Antioxidant SS-31 Reverses Some Measures of Aging in Muscle - May 26th, 2013
- Arguing for the Role of Nuclear DNA Damage in Aging - May 26th, 2013
- Reviewing the Results of Calorie Restriction Primate Studies - May 19th, 2013
- A Possible Biomarker for Senescent Cells - May 19th, 2013
- Inhibiting ICMT as a Progeria Therapy - May 19th, 2013
- Are the Most Influential Futurists Those Who Put in the Work to Make Their Visions Real? - May 19th, 2013
- Excess Body Fat Hardens Arteries - May 19th, 2013
- Comments on Rapamycin and Metformin - May 12th, 2013
- The Present State of Artificial Retinas - May 12th, 2013
- The State of Electromechanical and Bioartifical Organs - May 12th, 2013
- Parabiosis Points to GDF-11 as a Means to Reverse Age-Related Cardiac Hypertrophy - May 12th, 2013
- Insights into Inflammaging - May 12th, 2013
- A Different Take on NF-?B and the Hypothalamus - May 5th, 2013
- T-Regulatory Cells More Numerous in the Aged Immune System - May 5th, 2013
- HMGA1 as a Potential Common Mechanism in Cancer - May 5th, 2013
- Recent Research Results from the Study of Naked Mole Rats - May 5th, 2013
- A Skeptical View of Mitochondrial DNA Damage and Aging - May 5th, 2013
- Recent Calorie Restriction Research - April 28th, 2013
- Joining the Dots in Genetic Parkinson's Disease - April 28th, 2013
- Considering the Electron Transport Chain in Aging - April 28th, 2013
- More Data on Granulocyte Transplant Cancer Therapies - April 28th, 2013
- Measures of Mitochondrial DNA Damage Lower in Long-Lived Mice - April 28th, 2013
- Aubrey de Grey on "The Undoing of Aging" - April 21st, 2013
- Mitochondrial Functional Mutations and Worm Longevity - April 21st, 2013
- Indy Mutations and Fly Longevity - April 21st, 2013
- Further Research on BubR1, Cellular Senescence, and Aging - April 21st, 2013
- Sterilized Dogs Live Longer - April 21st, 2013
- Robust Cancer Therapies Will Mean a Greater Use of Aggressive Stem Cell Therapies - April 14th, 2013